Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2007

View Archived Issues

Minodronate effective in Japanese women with postmenopausal osteoporosis

Symphony GenIsis acquired by Isis

Patient enrollment completed in Barrier's pivotal phase III trial of Hyphanox

Osteopontin: a novel target for the treatment of uveoretinitis

Local delivery of VIP-loaded liposomes effectively protects ocular tissue in rats with EAU

Preclinical efficacy, pharmacokinetics and safety of the ETB agonist SPI-1620

Actelion begins phase IIa proof-of-concept study of Zavesca for CF

First patients enrolled in Transgene's phase I trial of HCV vaccine TG-4040

Recordati to acquire Orphan Europe

Positive results for Diffusion's phase I safety trial of TSC

BioLineRx in-licenses novel peptide for cancer

Phase II studies commence for PYY3-36 nasal spray to treat obesity

RDEA-119 enters human clinical trials in advanced cancer patients

Merck & Co. donates cervical cancer vaccine Gardasil in lowest income nations

Nemonoxacin's preclinical profile reported

AR-2474: a novel topical antibiotic against MRSA infections

Novel contraceptive agents imparted by Pharmacopeia

Recent Ferring patent reports novel agents for use in critical care medicine

Taxotere receives FDA approval for expanded SCCHN indication

Novel immunosuppressant agents disclosed in recent Synta patent

Oncolytics Biotech reports positive interim data from combination Reolysin/radiation trial

Sublinox shows promise in comparative study for sleep disturbances

Novel antihypertensive agents prepared and tested at Torrent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...